Weight-Loss Drugmaker Demands NHS Price Hikes to Boost UK Investment

The pharmaceutical giant behind the popular weight-loss drug Mounjaro is pressuring the UK government to regularly increase NHS drug prices and end a rebate scheme in exchange for renewed investment in the country.

Eli Lilly, the US-based company that manufactures Mounjaro, is currently in talks with UK ministers and is optimistic about reaching an agreement this summer for Britain to pay more for its medicines.

Patrik Jonsson, the president of Eli Lilly's international business, said the company had paused its UK investments but would be willing to unpause those plans if the government meets its demands.

The move comes as the NHS grapples with rising drug costs and faces pressure to rein in spending. Eli Lilly's push for higher prices and an end to the rebate scheme is likely to be met with resistance from the government, which has prioritized containing healthcare costs.

However, Jonsson argued that increased investment in the UK by Eli Lilly would bring economic benefits and support the country's pharmaceutical industry. He emphasized the company's desire to deepen its ties with the UK and contribute to the country's life sciences sector.

The negotiations between Eli Lilly and the UK government will be closely watched, as the outcome could set a precedent for how the NHS handles drug pricing and negotiations with pharmaceutical companies. The balance between ensuring affordable access to essential medicines and incentivizing investment in the UK's life sciences sector will be a key challenge.

As the debate over drug pricing and healthcare costs continues, the Mounjaro maker's demands will likely spark further discussions and scrutiny around the complex relationship between the pharmaceutical industry and national health systems.